Literature DB >> 16217074

Evidence for progressive gray matter loss in patients with relapsing-remitting MS.

P Valsasina1, B Benedetti, M Rovaris, M P Sormani, G Comi, M Filippi.   

Abstract

Little is known about the temporal evolution of gray matter damage occurring early in the course of multiple sclerosis (MS). The authors investigated the evolution of gray matter volume loss in 117 patients with relapsing-remitting MS, scanned monthly for a 9-month period. Time-trend analysis revealed a decrease of gray matter volumes over the study period (p < 0.001). This study shows that gray matter damage in relapsing-remitting MS evolves markedly over a short period of observation.

Entities:  

Mesh：

Year:  2005        PMID： 16217074     DOI： 10.1212/01.wnl.0000178982.53965.70

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

3.  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Authors:  J Furby; T Hayton; D Altmann; R Brenner; J Chataway; K J Smith; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2010-05-01       Impact factor: 4.849

4.  Corpus callosum index and long-term disability in multiple sclerosis patients.

Authors:  Ozgür Yaldizli; Ramin Atefy; Achim Gass; Dietrich Sturm; Stephanie Glassl; Barbara Tettenborn; Norman Putzki
Journal:  J Neurol       Date:  2010-03-03       Impact factor: 4.849

5.  3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis.

Authors:  Mohit Neema; Daniel Goldberg-Zimring; Zachary D Guss; Brian C Healy; Charles R G Guttmann; Maria K Houtchens; Howard L Weiner; Mark A Horsfield; David B Hackney; David C Alsop; Rohit Bakshi
Journal:  Neuroimage       Date:  2009-03-10       Impact factor: 6.556

Review 6.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

7.  Proteomic strategies in multiple sclerosis and its animal models.

Authors:  Stella Elkabes; Hong Li
Journal:  Proteomics Clin Appl       Date:  2007-10-16       Impact factor: 3.494

8.  Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis.

Authors:  Cornelia Cudrici; Takahiro Ito; Ekaterina Zafranskaia; Florin Niculescu; Katherine M Mullen; Sonia Vlaicu; Susan I V Judge; Peter A Calabresi; Horea Rus
Journal:  Exp Mol Pathol       Date:  2007-07-06       Impact factor: 3.362

9.  Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis.

Authors:  B Healy; P Valsasina; M Filippi; R Bakshi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

10.  Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.

Authors:  Allan MacKenzie-Graham; Florian Kurth; Yuichiro Itoh; He-Jing Wang; Michael J Montag; Robert Elashoff; Rhonda R Voskuhl
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.